OCULAR THERAPEUTIX, INC

OCUL Nasdaq CIK: 0001393434

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 15 CROSBY DRIVE, BEDFORD, MA, 01730
Mailing Address 15 CROSBY DRIVE, BEDFORD, MA, 01730
Phone 781-357-4000
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

-$80.74M
Net Income
$153.75M
Total Liabilities
$-1.42
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment February 10, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 10, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
10-K Annual financial report February 5, 2026 View on SEC
4 Insider stock transaction report February 4, 2026 View on SEC
4 Insider stock transaction report January 26, 2026 View on SEC
3 Initial insider ownership report January 26, 2026 View on SEC
8-K Current report of material events January 23, 2026 View on SEC
3 Initial insider ownership report January 22, 2026 View on SEC
4 Insider stock transaction report January 22, 2026 View on SEC

Annual Reports

10-K February 5, 2026
  • Strong revenue growth for DEXTENZA®, with a 28% increase to $68.5 million in 2023.
  • Reduced net loss year-over-year, improving from $148.9 million to $125.3 million.
View Analysis

Material Events

8-K Other December 5, 2025
High Impact
  • OCULAR THERAPEUTIX, INC. filed an official report detailing its plans and significant regulatory hurdles for FDA approval of its key eye drug, AXPAXLI (OTX-TKI).
  • AXPAXLI is a crucial product for treating wet age-related macular degeneration (wet AMD), and its success or failure will significantly impact the company's future.
View Analysis

Insider Trading

SELL 5 insiders 6 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.